CA2695167C - Methods for the treatment of elevated cholesterol levels - Google Patents

Methods for the treatment of elevated cholesterol levels Download PDF

Info

Publication number
CA2695167C
CA2695167C CA2695167A CA2695167A CA2695167C CA 2695167 C CA2695167 C CA 2695167C CA 2695167 A CA2695167 A CA 2695167A CA 2695167 A CA2695167 A CA 2695167A CA 2695167 C CA2695167 C CA 2695167C
Authority
CA
Canada
Prior art keywords
alkyl
acyl
sdat
glycerol
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2695167A
Other languages
English (en)
French (fr)
Other versions
CA2695167A1 (en
Inventor
Dayan Goodenowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Med-Life Discoveries Lp
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Publication of CA2695167A1 publication Critical patent/CA2695167A1/en
Application granted granted Critical
Publication of CA2695167C publication Critical patent/CA2695167C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2695167A 2007-02-08 2007-08-27 Methods for the treatment of elevated cholesterol levels Active CA2695167C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88888307P 2007-02-08 2007-02-08
US60/888,883 2007-02-08
CA2620274A CA2620274C (en) 2007-02-08 2007-08-27 Methods for the treatment of senile dementia of the alzheimer's type

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2620274A Division CA2620274C (en) 2007-02-08 2007-08-27 Methods for the treatment of senile dementia of the alzheimer's type

Publications (2)

Publication Number Publication Date
CA2695167A1 CA2695167A1 (en) 2008-06-20
CA2695167C true CA2695167C (en) 2011-11-01

Family

ID=39537686

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2695167A Active CA2695167C (en) 2007-02-08 2007-08-27 Methods for the treatment of elevated cholesterol levels
CA2620274A Active CA2620274C (en) 2007-02-08 2007-08-27 Methods for the treatment of senile dementia of the alzheimer's type

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2620274A Active CA2620274C (en) 2007-02-08 2007-08-27 Methods for the treatment of senile dementia of the alzheimer's type

Country Status (8)

Country Link
US (5) US9034923B2 (https=)
EP (2) EP2117527B1 (https=)
JP (1) JP5470050B2 (https=)
AU (1) AU2007346587C1 (https=)
CA (2) CA2695167C (https=)
IL (1) IL200029A0 (https=)
SG (1) SG173418A1 (https=)
WO (1) WO2008095275A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117527B1 (en) 2007-02-08 2020-06-17 Med-Life Discoveries LP Compounds for use in the treatment of senile dementia of the alzheimer's type
TWI475989B (zh) * 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法
EP3124980A1 (en) 2009-10-01 2017-02-01 Phenomenome Discoveries Inc. Mass spectrophotometric method to diagnose pancreatic cancer
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN114236019B (zh) * 2022-02-24 2022-05-06 宝枫生物科技（北京）有限公司 脑白质病变的生物标志物的应用
WO2025057966A1 (ja) * 2023-09-12 2025-03-20 シンバイオシス・ソリューションズ株式会社 軽度認知障害の予防又は改善用の食品
CN118512461A (zh) * 2024-06-03 2024-08-20 东莞市第八人民医院（东莞市儿童医院） 一种母乳来源磷脂在防治支气管肺发育不良的应用
CN119876292B (zh) * 2025-03-27 2025-06-03 浙江省白马湖实验室有限公司 一种酰胺类缩醛磷脂化合物的制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009371A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
FR2736265B1 (fr) 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US5731354A (en) 1996-05-06 1998-03-24 Clarion Pharmaceuticals Inc. Treatment for the inhibition of neuro-degenerative disease states
US6177476B1 (en) 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
US20020009740A1 (en) 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001286059A1 (en) 2000-09-08 2002-03-22 Oxford Glycosciences (Uk) Ltd. Automated identification of peptides
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
WO2002082075A2 (de) 2001-04-06 2002-10-17 Biovision Ag Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
CA2446666A1 (en) 2001-05-09 2002-11-14 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
EP1504419B1 (en) 2002-03-22 2011-05-04 Phenomenome Discoveries Inc. Method of visualizing non-targeted metabolomic data generated from fourier transform ion cyclotron resonance mass spectrometers
JP2004026803A (ja) * 2002-03-29 2004-01-29 Nof Corp 神経細胞死予防剤
CA2745998C (en) 2002-08-23 2013-11-26 Bayer Schering Pharma Aktiengesellschaft Biomarkers for diagnosing alzheimer's disease
SE0203886D0 (sv) * 2002-12-27 2002-12-27 Ltp Lipid Technologies Provide Glycerolesterprodukt och dess användning
US20040191294A1 (en) * 2003-03-27 2004-09-30 Ramaprasad Talahalli Ravichandra Health composition
US20070037882A1 (en) 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
WO2005085838A2 (en) 2004-03-02 2005-09-15 Vanderbilt University Computational analysis of mass spectroscopic lipid data
WO2005116659A2 (en) 2004-05-18 2005-12-08 Neurodx, Llc Compositions and methods relating to alzheimer’s disease
WO2007002285A2 (en) * 2005-06-21 2007-01-04 The Trustees Of The University Of Pennsylvania Methods for treating neurological and psychiatric conditions
JP4176749B2 (ja) 2005-07-29 2008-11-05 学校法人帝京大学 疾病検査法
SG165370A1 (en) 2005-09-12 2010-10-28 Phenomenome Discoveries Inc Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
WO2007030948A1 (en) 2005-09-15 2007-03-22 Phenomenome Discoveries Inc. Method and apparatus for fourier transform ion cyclotron resonance mass spectrometry
CA2689848A1 (en) 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
AU2007266218C1 (en) 2006-05-26 2013-05-23 Phenomenome Discoveries Inc. Biomarkers for diagnosing multiple sclerosis, and methods thereof
US20100105635A1 (en) 2007-01-30 2010-04-29 Tohoku University Composition for prevention or treatment of disease associated with amyloidosis through inhibition of amyloid protein aggregation and promotion of amyloid protein degradation
EP2117527B1 (en) 2007-02-08 2020-06-17 Med-Life Discoveries LP Compounds for use in the treatment of senile dementia of the alzheimer's type
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders

Also Published As

Publication number Publication date
EP2620147A3 (en) 2013-10-02
EP2620147B1 (en) 2020-06-03
US20130046016A1 (en) 2013-02-21
US9517222B2 (en) 2016-12-13
EP2117527A1 (en) 2009-11-18
SG173418A1 (en) 2011-08-29
EP2117527B1 (en) 2020-06-17
US10123989B2 (en) 2018-11-13
CA2695167A1 (en) 2008-06-20
CA2620274C (en) 2011-10-04
EP2620147A2 (en) 2013-07-31
US20160015673A1 (en) 2016-01-21
AU2007346587A1 (en) 2008-08-14
CA2620274A1 (en) 2008-06-20
AU2007346587C1 (en) 2015-01-22
US8993623B2 (en) 2015-03-31
US20120129934A1 (en) 2012-05-24
US9034923B2 (en) 2015-05-19
AU2007346587B2 (en) 2014-03-27
US20150306057A1 (en) 2015-10-29
WO2008095275A1 (en) 2008-08-14
IL200029A0 (en) 2010-04-15
JP5470050B2 (ja) 2014-04-16
US20170056363A1 (en) 2017-03-02
JP2010518029A (ja) 2010-05-27
EP2117527A4 (en) 2012-09-12

Similar Documents

Publication Publication Date Title
CA2695167C (en) Methods for the treatment of elevated cholesterol levels
USRE49238E1 (en) Alleviating oxidative stress disorders with PUFA derivatives
Han Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer’s disease: a tale of shotgun lipidomics
Song et al. Effects of dietary glucocerebrosides from sea cucumber on the brain sphingolipid profiles of mouse models of Alzheimer's disease
Meletis Alkyl-acylglycerols and the important clinical ramifications of raising plasmalogens in dementia and Alzheimer’s disease
EP0543922A1 (en) Methods for inducing cell differentiation using ceramides
Sibomana et al. Influence of myo-inositol plus ethanolamine on plasmalogens and cell viability during oxidative stress
AU2014201707B2 (en) Methods for the treatment of Senile Dementia of the Alzheimer's Type
HK1182935A (en) Compounds for lowering cholesterol
HK1182935B (en) Compounds for lowering cholesterol
HK1131348B (en) Compounds for use in the treatment of senile dementia of the alzheimer's type
HK1131348A (en) Compounds for use in the treatment of senile dementia of the alzheimer's type
Supruniuk et al. Lipid peroxidation and sphingolipid alterations in the cerebral cortex and hypothalamus of rats fed a high-protein diet
Rossi Multitarget and network-driven medicinal chemistry strategies for the treatment of neuroinflammatory diseases
Saitoh et al. Changes in the amounts of myelin lipids and molecular species of plasmalogen PE in the brain of an autopsy case with d-bifunctional protein deficiency
HK40013804A (en) Alleviating oxidative stress disorders with pufa derivatives
WO2020264324A1 (en) Use of certain phosphatidylcholines containing long chain polyunsaturated fatty acids as neuroprotective agents
WO2007094026A1 (en) Prophylactic and/or therapeutic treatment of proliferative and conformational diseases

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241021